Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - October 20, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/17 - "A Pharmaceutical Composition for the Treatment of Multi-Drug Resistant Infections" in Patent Application Approval Process (USPTO 20170273939)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors VISHWAKARMA, Ram; KUMAR, Ajay; KHAN, Inshad Ali; BHARATE, Sandip Bibishan; JOSHI, Prashant; SINGH, Samsher; SATTI, Naresh, filed on October 21, 2015, was made available online on October 5, 2017, according to news reporting originating from Washington, D.C., b
10/20/17 - "Pharmaceutical Composition for Topical Administration" in Patent Application Approval Process (USPTO 20170273945)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors LIU, Wai Leung; PURKINS, Lynn; YEADON, Michael, filed on June 9, 2017, was made available online on October 5, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a com
10/20/17 - 2017 DrugDev Summit, Co-Chaired by Novartis and CSL Behring, to Convene 100+ Clinical Leaders to Improve the Clinical Trial Experience for Patients, Sites and Study Teams [Sport360]
-The worlds most progressive pharmaceutical companies, CROs and sites will continue to advance beyond the clinical trial status quo at the 2017 DrugDev Summit in Philadelphia, November 7-8. Co-chaired by Novartis and CSL Behring, DrugDevs annual Summit is widely regarded by customers as the premier open forum for sharing clinical trial best practic
10/20/17 - Abbott Reports Third Quarter 2017 Results
Excluding specified items, adjusted diluted EPS from continuing operations was $0.66 in the third quarter, at the high end of the previous guidance range of $0.64 to $0.66. In September, Abbott received U.S. FDA approval for its FreeStyle Libre glucose monitoring system as a replacement1 for finger stick blood glucose monitoring. During the quarter
10/20/17 - AcelRx's DSUVIA? Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY 2017
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical, today announced its clinical data presentation on the safety and efficacy of DSUVIA?, 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists' ANESTHESIOLOGY 2017 Annual Meeting. The information presented during the session was authored
10/20/17 - Adverse events spike after blood pressure meds go generic in Canada
By a News Reporter-Staff News Editor at Drug Week DALLAS, One month after generic versions of three widely-used blood pressure drugs became available in Canada, hospital visits for adverse events spiked in generic drug users, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
10/20/17 - AG Laxalt Launches 'Nevada's Prescription for Addiction' Opioid Initiative
Nevada Attorney General Adam Paul Laxalt issued the following statement after the Interim Finance Committee's unanimous, bipartisan approval of his office's "Prescription for Addiction" opioid initiative to combat the use, abuse and misuse of prescription drugs in Nevada:. My office's' Prescription for Addiction' opioid initiative creates an opport
10/20/17 - Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares
The ADSs described above are being offered by Akari pursuant to its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission and declared effective by the SEC on August 20, 2014. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be f
10/20/17 - Alnylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloidosis, will be presented at the 1 st European ATTR Amyloidosis Meeting for Patients an
10/20/17 - Alnylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases
CAMBRIDGE, Mass.- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people with serious infectious diseases, for the development and commercialization of RNAi therapeutics for infectious diseases, including...
10/20/17 - An Application for the Trademark "ANTABUSE" Has Been Filed by Teva Pharmaceuticals USA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "ANTABUSE" by Herschel Perel, representing Teva Pharmaceuticals USA. The owner/registrar information for this application is: Herschel Perel, Teva Pharmaceuticals USA, Tr
10/20/17 - An Application for the Trademark "DP" Has Been Filed by Teva Pharmaceuticals USA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "DP" by Herschel Perel, representing Teva Pharmaceuticals USA. The owner/registrar information for this application is: Herschel Perel, Teva Pharmaceuticals USA, Trademar
10/20/17 - Anemia Prevalence Promotes Growth Of Hematology Drugs Market
The market leader is Danish company Novo Nordisk, followed by the UK' s Shire and Germany' s Bayer. One of the trends shaping the market is an increase in product approvals for hemophilia. The increase in the number of drug approvals for hemophilia by the regulatory bodies such as FDA in the US is an emerging trend in the market. For instance, in J
10/20/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report: (Oct. 3, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on October 3, 2017. The SEC file number is 0001104659-17-060416.. A U.S. Securities and Exchange Commission filing is a forma
10/20/17 - Arbutus Biopharma Corp. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material: (Oct. 3, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on October 3, 2017. The SEC file number is 0001104659-17-060417.. A U.S. Securities and Exchange Commission filing is a forma
10/20/17 - Arbutus Biopharma Corp. Files SEC Form SC 13D/A, General Statement of Acquisition of Beneficial Ownership: (Oct. 3, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on October 3, 2017. The SEC file number is 0001104659-17-060395.. A U.S. Securities and Exchange Commission filing is a forma
10/20/17 - Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines [Tehran Times (Iran)]
-Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson& Johnson. The deal was facilitated by the Johnson& Johnson Innovation center, in California.
10/20/17 - Array Biopharma Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities: (Sept. 29, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on September 29, 2017. The SEC file number is 0001562180-17-003064.. A U.S. Securities and Exchange Commission filing is a forma
10/20/17 - AstraZeneca - US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Imfinzi for the treatment of patients with locally advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum..
10/20/17 - AtriCure to Present at the Stifel Healthcare Conference
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that it will present at the Stifel Healthcare Conference at the Palace Hotel in New York on Tuesday, November 14, 2017. AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditi
10/20/17 - Autosamplers Market Worth 1136.2 Million USD by 2022
According to a new market research report " Autosamplers Market by Product (Systems (Liquid Chromatography, GC (Liquid, Headspace, All-in-one)), Accessories (Syringe& Needle, Vial, Septum)& Enduser (Pharmaceutical companies, Oil& Gas, Food& Beverage, Environment testing)- Global Forecasts to 2022", published by MarketsandMarkets?, the market is p
10/20/17 - Avadel Pharmaceuticals to Report Third Quarter 2017 Results
Avadel Pharmaceuticals plc, today announced it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, before the market open. About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and eas
10/20/17 - AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission
AzurRx BioPharma Inc., announced the submission of an Investigational Medicinal Product Dossier for its lead product MS1819-SD, a recombinant lipase for the treatment of exocrine pancreatic insufficiency caused by chronic pancreatitis and cystic fibrosis.. This Investigational Medicinal Product Dossier has been submitted through the European...
10/20/17 - Azurrx Biopharma, Inc. Files SEC Form 8-K, Current Report: (Oct. 2, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Azurrx Biopharma, Inc. was posted on October 2, 2017. The SEC file number is 0001654954-17-009038.. A U.S. Securities and Exchange Commission filing is a formal
10/20/17 - Azurrx Biopharma, Inc. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans: (Oct. 3, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Azurrx Biopharma, Inc. was posted on October 3, 2017. The SEC file number is 0001654954-17-009085.. A U.S. Securities and Exchange Commission filing is a formal
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415